Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Stanford University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT01129778
First received: May 21, 2010
Last updated: May 24, 2010
Last verified: May 2010

May 21, 2010
May 24, 2010
November 2009
July 2010   (final data collection date for primary outcome measure)
Control of esophageal pH [ Time Frame: 1 month ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01129778 on ClinicalTrials.gov Archive Site
Control of GERD symptoms [ Time Frame: 1 month ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus
Assessment of the Effects of Zegerid Powder for Oral Suspension 40 mg on 24-Hour and Nocturnal Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease and Barrett's Esophagus

The purpose of this research study is to assess how safe, effective (how well it works), and tolerable (to put up with) the drug Zegerid is in reducing reflux episodes in patients who have both gastroesophageal reflux disease (GERD) and Barrett's esophagus. Zegerid has been approved by the US Food and Drug Administration (FDA) for the treatment of GERD. The investigators hope to learn the effectiveness of Zegerid for reducing the amount of acid reflux patients are experiencing in the esophagus (swallowing pipe).

The following procedures will be performed at the Screening Visit:

  • Obtain informed consent.
  • Obtain information about your age and gender.
  • Evaluate whether you qualify for the study.
  • Document prior negative testing for H. pylori infection (a bacterial infection in the stomach that can cause ulcers) including the date of testing.
  • Make sure that you have not used any investigational medications or participated in a clinical trial in the 30 days prior to the Screening Visit.
  • Obtain medical history.
  • Record medication history (including concomitant medications).
  • Obtain vital signs.
  • Conduct a physical examination.
  • If a Bravo pH study has not been done within 8 weeks, instruct the patient to discontinue their medication for GERD during the 7-10 day washout period.
  • Instruct the patient to discontinue the use of all prohibited medications during the applicable time intervals and not to start any new concomitant medications during the trial.
  • Distribute Gelusil tablets to be used as "rescue medication"; instruct the patient that no more than 6 Gelusil tablets per day or 21 tablets over any 7-day interval will be allowed.
  • Schedule the patient to return for the Qualification Visit, or for pH monitoring and the Qualification Visit. Only patients with abnormal pH monitoring will be able to enter the treatment period.

Procedures that will occur during the Treatment Period:

  • You will receive Zegerid 1 hour before breakfast and at bedtime for at least 14 days and no longer than 28 days
  • At the end of the Zegerid treatment period, you will undergo 48-hour Bravo pH monitoring on Zegerid therapy for two days. You will complete a symptom survey and quality of life survey after the completion of the pH study.
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Barrett Esophagus
  • Gastroesophageal Reflux
  • Drug: Zegerid (proton pump inhibitor)
  • Procedure: Bravo pH monitoring
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
December 2010
July 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Inclusion criteria include adult men and women (aged ≥18 years) with previously established, biopsy-proven diagnosis of BE (any length intestinal metaplasia without dysplasia or adenocarcinoma)

Exclusion Criteria:

  • Exclusion criteria include a history of esophageal, gastric, or duodenal surgery (including antireflux surgery or endoscopic antireflux procedures), except for simple ulcer closure
  • Zollinger-Ellison syndrome
  • Endoscopic evidence or suspicion of a pathologic or infiltrative process in the stomach
  • Positive for H. pylori.
Both
Not Provided
No
Contact: Lauren Gerson (650) 725-3376 lgerson@stanford.edu
United States
 
NCT01129778
SU-04302010-5803
Not Provided
Lauren B Gerson, Stanford University School of Medicine
Stanford University
Not Provided
Principal Investigator: Lauren B Gerson Stanford University
Stanford University
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP